SEC Form 4 · accession 0001140361-17-014413
Asterias Biotherapeutics, Inc. · AST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jane Lebkowski
Officer — President of R&D
Period of report
Mar 30, 2017
Accepted (ET)
Apr 3, 2017 · 5:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001572552
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 30, 2017 | A | 17,670 | $0.00 | A | 35,006 | D | |
| Restricted Stock Units to be settled in Common StockF1 | Mar 30, 2017 | A | 75,000 | $0.00 | A | 110,006 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The restricted stock units vest in four equal annual installments on the first, second, third and fourth anniversaries of the grant date.